Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Noga Therapeutics Ltd. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This case is assigned to NGUYEN, QUANG, who is the busiest examiner for the portfolio with 1 pending office action. The company's current prosecution activity involves 1 distinct examiner and 1 distinct art unit. The presence of 1 pending office action total suggests a focused approach to intellectual property in the Biotechnology & Pharmaceuticals sector.
Because the portfolio is handled by only 1 distinct examiner, NGUYEN, QUANG, the applicant can dedicate its resources to resolving the specific issues raised in this single matter. This concentration within 1 distinct art unit indicates that the company's current innovations are being evaluated within a narrow technical scope. This centralized workload allows for a targeted prosecution approach that minimizes the need for broad administrative oversight. Practitioners should focus on the specific technical standards of the Biotechnology & Pharmaceuticals area to address the examiner's concerns. The resolution of this matter is critical for the company's patent landscape, as it represents the only active prosecution path at this time. This focused approach ensures that all legal and technical resources are directed toward a single, high-priority goal, potentially leading to a more efficient path to allowance and a stronger competitive position.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, QUANG | 1 | 37.9% | +52.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18265773 | LENTIVIRAL VECTORS FOR THERAPEUTIC EXPRESSION OF BTK IN HEMATOPOIETIC CELLS | NGUYEN, QUANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18265773 | LENTIVIRAL VECTORS FOR THERAPEUTIC EXPRESSION OF BTK IN HEMATOPOIETIC CELLS | NGUYEN, QUANG | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18265773 | LENTIVIRAL VECTORS FOR THERAPEUTIC EXPRESSION OF BTK IN HEMATOPOIETIC CELLS | NGUYEN, QUANG | 1631 | §101§102§103§112DP | Non-Final OA | — | Pending | Jun 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNoga Therapeutics Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Quang Nguyen has the most, with 1 of Noga Therapeutics Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
